SHORT REPORT

Are heterogenous results of EGFR immunoreactivity in renal cell carcinoma related to non-standardised criteria for staining evaluation?

C Langner, M Ratschek, P Rehak, L Schips, R Zigeuner

MATERIALS AND METHODS

Paraffin wax embedded specimens from 132 primary conventional (clear cell) RCCs and 53 unrelated conventional RCC metastases were selected for analysis. The pT stages of the primary tumours were assessed according to the UICC 2003 issue of the TNM system and the nuclear grades were assessed according to the Fuhrman grading system. For immunohistochemistry, a tissue microarray technique was used that included three cylindrical core biopsies (0.6 mm in diameter) taken from different sites of each tumour. EGFR immunoreactivity was investigated using the EGFR pharmDx™ kit (DakoCytomation, Glostrup, Denmark). Membranous and/or cytoplasmic staining was considered positive and the total percentage of tumour cells stained was categorised as either “focal” (+; < 10% of tumour cells positive), “moderate” (++; 10–50% positive), or “extensive” (+++; > 50% positive). In another step, only the cytoplasmic staining was assessed according to the same criteria. Finally, the intensity of membranous immunostaining was categorised as either “weak” (score 1+), “moderate” (score 2+), or “strong” (score 3+). For statistical analysis, subgroups according to pT category, grade, and histological subtype were compared using the \( \chi^2 \) test or Fisher’s exact test, respectively. Disease free survival in conventional cancers was investigated using the Kaplan-Meier method and compared by the log rank test. Cox’s proportional hazards regression model was used for multivariate testing.

RESULTS

Overall, membranous and/or cytoplasmic EGFR immunostaining was present in 123 of 132 (93%) primary and 49 of 53 (92%) metastatic conventional RCCs with extensive immunoreactivity in 110 of 132 (83%) primary tumours and 39 of 53 (73%) metastases. Cytoplasmic staining was associated with high tumour stage and high tumour grade. In addition, strong membranous staining (score 3+) prevailed in high grade RCCs. Cytoplasmic immunostaining was associated with an unfavourable prognosis, whereas overall (cytoplasmic and membranous) immunoreactivity and intensity of membranous staining were not.

CONCLUSIONS

Different methods of immunohistochemical evaluation led to different results, strengthening the need for standardisation, especially against a background of rapidly evolving EGFR targeted cancer treatment strategies.
with disease free survival because 26 of 86 patients with RCCs showing cytoplasmic immunoreactivity developed progressive disease, compared with three of 41 patients without cytoplasmic staining (p = 0.001). Multivariate analysis, however, proved pT stages 3a/3b (risk ratio, 3.5; p = 0.026) and grades 3/4 (risk ratio, 16.7; p < 0.001) to be the only independent prognostic markers, whereas for cytoplasmic EGFR staining only a trend was noted (risk ratio, 3.3; p = 0.07).

**DISCUSSION**

Renal cancer is known to be largely resistant to conventional chemotherapy. The frequent expression of EGFR in RCCs in our series, which was shown for the first time both in primary and in metastatic tumour tissues, makes this type of cancer a promising candidate for EGFR targeted tumour treatment. However, the identification of those patients who might benefit from this treatment currently relies on non-standardised criteria for the interpretation of EGFR immunostaining. In our study, three different methods of immunohistochemical evaluation, which were all part of the "pathology report form" recommended by the manufacturer of the detection kit used, were applied and shown to yield different results with respect to associations with tumour stage and grade, in addition to the patients' outcome.

"Future studies should be aimed at answering the question of whether different patterns of immunoreactivity (membranous versus cytoplasmic) might help select patients for different approaches of epidermal growth factor receptor targeted treatment".

Thus, our results may explain the conflicting data in the literature: some studies showed an association of EGFR immunoreactivity with well differentiated RCCs, or regarded strong membranous EGFR immunostaining as an indicator of good prognosis, whereas others showed an association of EGFR immunoreactivity with high tumour stage/grade and poor prognosis, or no significant associations at all.

Surgical pathologists are currently faced with growing clinical requests regarding EGFR immunostaining in several types of cancer. However, to provide a reliable basis for a tailored cancer treatment a standardisation of the criteria for the evaluation of EGFR immunostaining is indispensable. Moreover, future studies should be aimed at answering the question of whether different patterns of immunoreactivity (membranous versus cytoplasmic) might help select patients for different approaches of EGFR targeted treatment—for example, monoclonal antibodies that interfere with cell membrane receptor proteins or specific low molecular weight inhibitors of intracellular tyrosine kinases.

**Table 1** Membranous and/or cytoplasmic EGFR immunoreactivity and intensity of membranous staining in RCC, in addition to the relation between strong membranous EGFR immunostaining and pT category and tumour grade

<table>
<thead>
<tr>
<th>Overall immunoreactivity</th>
<th>N</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Negative</td>
<td>9</td>
<td>7</td>
</tr>
<tr>
<td>+</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>++</td>
<td>11</td>
<td>8</td>
</tr>
<tr>
<td>+++</td>
<td>110</td>
<td>83</td>
</tr>
<tr>
<td>Membranous staining</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Score 0</td>
<td>10</td>
<td>8</td>
</tr>
<tr>
<td>Score 1+</td>
<td>18</td>
<td>14</td>
</tr>
<tr>
<td>Score 2+</td>
<td>24</td>
<td>18</td>
</tr>
<tr>
<td>Score 3+</td>
<td>80</td>
<td>61</td>
</tr>
<tr>
<td>Stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>pT1a</td>
<td>24/45</td>
<td>53</td>
</tr>
<tr>
<td>pT1b</td>
<td>15/21</td>
<td>71</td>
</tr>
<tr>
<td>pT2</td>
<td>2/5</td>
<td>40</td>
</tr>
<tr>
<td>pT3a</td>
<td>16/27</td>
<td>59</td>
</tr>
<tr>
<td>pT3b</td>
<td>23/34</td>
<td>68</td>
</tr>
<tr>
<td>Grade</td>
<td></td>
<td></td>
</tr>
<tr>
<td>G1</td>
<td>5/16</td>
<td>31</td>
</tr>
<tr>
<td>G2</td>
<td>41/68</td>
<td>60</td>
</tr>
<tr>
<td>G3</td>
<td>31/44</td>
<td>70</td>
</tr>
<tr>
<td>G4</td>
<td>3/4</td>
<td>75</td>
</tr>
</tbody>
</table>

EGFR, epidermal growth factor receptor; RCC, renal cell carcinoma.

**Take home messages**

- Membranous and/or cytoplasmic epidermal growth factor (EGFR) immunostaining was seen in 93% of primary and 92% of metastatic renal cell carcinoma (RCCs), with extensive immunoreactivity in 83% of primary tumours and 73% of metastases.
- Cytoplasmic immunostaining was associated with high tumour stage and high tumour grade and strong membranous immunostaining (score 3+) was seen in high grade RCCs.
- Cytoplasmic immunostaining was associated with an unfavourable prognosis, whereas overall (cytoplasmic and membranous) immunoreactivity and intensity of membranous staining were not.
- Different methods of immunohistochemical evaluation led to different results, strengthening the need for standardisation, especially with the emergence of EGFR targeted cancer treatment strategies.
Authors’ affiliations
C Langner, M Ratschek, Institute of Pathology, Medical University of Graz, Auenbruggerplatz 25, A-8036 Graz, Austria
P Rehak, Department of Surgery, Division of Biomedical Engineering and Computing, Medical University of Graz
L Schips, R Zigeuner, Department of Urology, Medical University of Graz

Correspondence to: Dr C Langner, Institute of Pathology, Medical University of Graz, Auenbruggerplatz 25, A-8036 Graz, Austria; cord.langner@meduni-graz.at

Accepted for publication 12 February 2004

REFERENCES
Are heterogenous results of EGFR immunoreactivity in renal cell carcinoma related to non-standardised criteria for staining evaluation?

C Langner, M Ratschek, P Rehak, L Schips and R Zigeuner

*J Clin Pathol* 2004 57: 773-775
doi: 10.1136/jcp.2003.015743

Updated information and services can be found at: [http://jcp.bmj.com/content/57/7/773](http://jcp.bmj.com/content/57/7/773)

These include:

**References**

This article cites 9 articles, 2 of which you can access for free at: [http://jcp.bmj.com/content/57/7/773#BIBL](http://jcp.bmj.com/content/57/7/773#BIBL)

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**

Articles on similar topics can be found in the following collections

- Immunology (including allergy) (1664)
- Urological cancer (164)

**Notes**

To request permissions go to: [http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to: [http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to: [http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)